Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 381

Is violent AI-human conflict inevitable?

Are you worried that artificial intelligence and humans will go to war? AI experts are. In 2023, a group of elite thinkers signed onto the Center for AI Safety’s statement that “Mitigating the risk of extinction from AI should be a global priority alongside other societal-scale risks such as pandemics and nuclear war.”

In a survey published in 2024, 38% to 51% of top-tier AI researchers assigned a probability of at least 10% to the statement “advanced AI leading to outcomes as bad as human extinction.”

The worry is not about the Large Language Models (LLMs) of today, which are essentially huge autocomplete machines, but about Advanced General Intelligence (AGI)—still hypothetical long-term planning agents that can substitute for human labor across a wide range of society’s economic systems.

Electrically tunable metasurface unlocks real-time THz holography

The terahertz (THz) band of the electromagnetic spectrum holds immense promise for next-generation technologies, including high-speed wireless communication, advanced encryption, and medical imaging. However, manipulating THz waves has long been a technical challenge, since these frequencies interact weakly with most natural materials.

Over the past two decades, researchers have increasingly turned to metasurfaces to tackle this problem. These are ultrathin materials carefully engineered to exhibit specialized properties, providing unprecedented control over THz waves.

Ideally, metasurfaces for THz applications in encryption and holography should be easily configurable, featuring an adjustable response that can be controlled externally. Despite this, tunable metasurface systems often rely on cumbersome or energy-inefficient methods, such as external thermal control.

Cancer-fighting gene plays unexpected role in pancreatic cancer tumor growth

New research from Indiana University School of Medicine scientists has revealed that a well-known cancer-fighting gene also plays an unexpected role in regulating how certain immune cells can support tumor growth. This insight into pancreatic cancer progression could lead to more effective treatments against one of the deadliest forms of cancer.

The study, recently published in Science Advances, focused on M2-like macrophages, a subtype of found in the tumor environment that are known to weaken the body’s ability to fight cancer. The researchers examined how a gene called serine/threonine kinase 11 (STK11) influences these cells. They found that when STK11 is missing in macrophages, those cells switch into a tumor-supporting state.

“STK11 was originally identified as a and extensive studies have examined the gene’s functions and mechanisms in regulating cancer cell growth,” said Kai Yang, PhD, corresponding author of the study, an associate professor of pediatrics and microbiology and immunology at the IU School of Medicine and a researcher with the Indiana University Melvin and Bren Simon Comprehensive Cancer Center.

How gene mutations drive dementia in Parkinson’s disease

Parkinson’s disease causes both movement and cognitive deficits, and for a long time both were thought to be caused by the accumulation of a protein called alpha-synuclein in the brain. But a new Nature Communications study has found that the cognitive deficits arise through a different—and unexpected—mechanism.

The new findings suggest that mutations in a gene called GBA—which are a risk factor for developing Parkinson’s disease—drive by disrupting how neurons communicate with each other in the brain. Patients living with Parkinson’s disease can experience such as difficulty with concentrating and forgetfulness. Over time, many go on to develop dementia, in which they experience profound memory loss among other symptoms.

“Dementia is often the scariest thing for many patients with Parkinson’s disease, more so than ,” says Sreeganga Chandra, PhD, professor of neurology and of neuroscience at Yale School of Medicine (YSM) and the study’s principal investigator. “We are trying to understand the basis of cognitive dysfunction and whether we can find targets to ameliorate it.”

New digital cognitive test for diagnosing Alzheimer’s disease

“The unique aspect of our BioCog test is that unlike other digital tests, it has been evaluated in a primary care population, i.e. patients seeking treatment at a health centre because they are experiencing cognitive problems, such as memory problems. Combining the results of the digital test and the blood test increases the accuracy of diagnosing Alzheimer’s disease. The purpose of the test is to make things easier for primary care doctors,” says one of the authors.

The digital test is done by the patient individually on a tablet computer. The test measures:

Alzheimer’s disease is the most common cause of dementia. As new disease-modifying treatments for Alzheimer’s disease are now becoming available, both early and accurate diagnosis in a resource-efficient assessment process are becoming increasingly important, as not everyone responds to the new drugs. Seeking medical care for cognitive impairment is not necessarily the result of Alzheimer’s disease – it can for example be caused by depression, fatigue or other dementias.

“Primary care does not have the resources, time or specialist knowledge to investigate possible Alzheimer’s disease in the same way as specialised memory clinics. And this is where a digital cognitive test can make the biggest difference,” says the senior author.

Unlike pen-and-paper tests, which are generally used to assess cognitive impairment, digital tests provide a more detailed picture. More aspects and new variables that could not previously be measured as easily are included.

Human genome rearrangement with programmable bridge recombinases

Bridge recombinases were discovered from parasitic mobile genetic elements that hijack bacterial genomes for their own survival. Presented last year in the journal Nature, the same team found these elements encode both a new class of structured guide RNA, which they named a “bridge RNA”, and a recombinase enzyme that rearranges DNA. The researchers repurposed this natural system by reprogramming the bridge RNA to target new DNA sequences, creating the foundation for a new type of precise gene editing tool they called bridge recombinases.

Starting with 72 different natural bridge recombinase systems isolated from bacteria, the team found that about 25% showed some activity in human cells, but most were barely detectable. Only one system, called ISCro4, showed enough measurable activity to enable further optimization. They then systematically improved both the protein and its RNA guide components, testing thousands of variations until they achieved 20% efficiency for DNA insertions and 82% specificity for hitting intended targets in the human genome.

While CRISPR uses a single guide RNA to target one DNA location, bridge RNAs are unique because they can simultaneously recognize two different DNA targets through distinct binding loops. This dual recognition enables the system to perform coordinated rearrangements such as bringing together distant chromosomal regions to excise genetic material or flipping existing sequences in reverse orientation. The system acts as molecular scaffolding that holds two DNA sites together while the recombinase enzyme performs the rearrangement reaction.

As a proof-of-concept, the researchers created artificial DNA constructs containing the same toxic repeat sequences that cause progressive neuromuscular decline in Friedreich’s ataxia patients. While healthy individuals carry fewer than 10 sequential copies of a three-letter DNA sequence, people with the disorder can harbor up to 1,700 copies, which interferes with normal gene function. The engineered ISCro4 successfully removed these repeats from the artificial constructs, in some cases eliminating over 80% of the expanded sequences.

The team also demonstrated that bridge recombinases could replicate existing therapeutic approaches by successfully removing the BCL11A enhancer, the same target disrupted in an FDA-approved sickle cell anemia treatment. And because bridge recombinases can move massive amounts of DNA, the technology could also help model the large-scale genomic rearrangements associated with cancers.

For decades, gene-editing science has been limited to making small, precise edits to human DNA, akin to correcting typos in the genetic code. The researchers are changing that paradigm with a universal gene editing system that allows for cutting and pasting of entire genomic paragraphs, rearranging whole chapters, and even restructuring entire passages of the genomic manuscript.

Continue reading “Human genome rearrangement with programmable bridge recombinases” | >

Inhaling cannabis may greatly increase your risk of getting asthma

If you’re looking to reduce your chances of developing lung disease, say experts at UC San Francisco, then it may be smart to avoid inhaling cannabis.

A new study in the Journal of General Internal Medicine found that inhaling marijuana every day is associated with a 44% increased chance of developing asthma. It also increased the odds of developing chronic obstructive pulmonary disease (COPD) by 27%.

The COPD risk may be understated, since the disease takes decades to develop, and the researchers did not have detailed information on how long people in the study had been using cannabis.

Galaxies Reveal Hidden Maps of Dark Matter in the Early Universe

Researchers uncover a key protein and a promising strategy to prevent bone damage from steroids.

The rheumatology and orthopedic researchers discovered that a protein called Basigin, which gets activated in stem cells when people take steroids, is a key reason why bones weaken and blood vessels in bone tissue become abnormal. By blocking Basigin, they were able to protect and even restore bone health in mice, suggesting a promising new treatment path.

Their findings were published in Nature Communications.

/* */